# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# Form 8-K

**Current Report** 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

January 26, 2006

**Date of Report** 

(Date of earliest event reported)

# **DURECT CORPORATION**

(Exact name of Registrant as specified in its charter)

Delaware (State or other jurisdiction of

incorporation or organization)

000-31615 (Commission File Number) 94-3297098 (I.R.S. Employer

Identification No.)

10240 Bubb Road

Cupertino, CA 95014

## Edgar Filing: DURECT CORP - Form 8-K

(Address of principal executive offices) (Zip code)

(408) 777-1417

(Registrant s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

" Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

" Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

" Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

" Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Item 8.01 Other Events.

On January 26, 2006, DURECT Corporation, a Delaware corporation (<u>DURECT</u>), issued a press release announcing that it plans expand its worldwide development program for its post-operative pain relief depot, SABER-Bupivacaine, by initiating additional Phase II studies for soft tissue and orthopedic surgical procedures. In addition, DURECT announced that clinical studies will be conducted in the U.S. under the accepted U.S. Investigational New Drug (IND) application for SABER-Bupivacaine. A copy of DURECT s press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.

#### Item 9.01. Financial Statements and Exhibits.

(c) Exhibits

99.1 Press Release of DURECT Corporation dated January 26, 2006

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

### **DURECT** Corporation

Date: January 26, 2006

By: /s/ James E. Brown

James E. Brown President and Chief Executive Officer

## DURECT CORPORATION

# INDEX TO EXHIBITS

Exhibit	
Number	Description
99.1	Press Release of DURECT Corporation dated January 26, 2006